Advertisement

The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma

  • Rachel Hu
  • Allison Winter
  • Brian T. HillEmail author
Lymphomas (MR Smith, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lymphomas

Abstract

Purpose of Review

Diffuse large B cell lymphoma (DLBCL) is characterized by clinical heterogeneity that is not fully accounted for by pathologic features. Furthermore, real-time treatment modifications and detection of relapse are typically guided by radiographic imaging modalities which are imperfect. Here, we review the potential utility of minimal residual disease (MRD) assessment for informing treatment decisions and detecting relapse.

Recent Findings

The most promising method of MRD detection is based on analysis of circulating tumor DNA in the peripheral blood of patients with DLBCL. This approach can predict outcomes and response to treatment as well as detect relapse prior to clinical signs of recurrent disease. While some studies of MRD in DLBCL have been in the prospective setting, the ability of this technology to alter clinical outcomes is currently unknown.

Summary

MRD detection provides a non-invasive way to gather information about DLBCL at various time points throughout the disease course. Its role is evolving and should be incorporated into prospective studies in order to demonstrate an impact on patient outcomes.

Keywords

Diffuse large B cell lymphoma Circulating tumor DNA Minimal residual disease Immunoglobulin next-generation sequencing Next generation sequencing 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59.  https://doi.org/10.3322/caac.21357.CrossRefPubMedGoogle Scholar
  2. 2.
    Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.  https://doi.org/10.1200/JCO.2010.28.1618.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Larouche JF, Berger F, Chassagne-Clement C, Ffrench M, Callet-Bauchu E, Sebban C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094–100.  https://doi.org/10.1200/JCO.2009.24.5860.CrossRefPubMedGoogle Scholar
  4. 4.
    Caimi PF, Hill BT, Hsi ED, Smith MR. Clinical approach to diffuse large B cell lymphoma. Blood Rev. 2016;30(6):477–91.  https://doi.org/10.1016/j.blre.2016.06.003.CrossRefPubMedGoogle Scholar
  5. 5.
    Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e17.  https://doi.org/10.1016/S2352-3026(18)30177-7.CrossRefPubMedGoogle Scholar
  6. 6.
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.  https://doi.org/10.1056/NEJMoa1707447.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.  https://doi.org/10.1056/NEJMoa1804980.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer. 2013;109(2):312–7.  https://doi.org/10.1038/bjc.2013.338.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90(2):165–71.  https://doi.org/10.1007/s00277-010-1044-8.CrossRefPubMedGoogle Scholar
  10. 10.
    Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33(23):2523–9.  https://doi.org/10.1200/JCO.2014.58.9846.CrossRefPubMedGoogle Scholar
  11. 11.
    Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32(31):3506–12.  https://doi.org/10.1200/JCO.2014.55.7561.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ. The international prognostic index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant. 2007;13(4):486–92.  https://doi.org/10.1016/j.bbmt.2006.12.452.CrossRefPubMedGoogle Scholar
  13. 13.
    •• Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679–87.  https://doi.org/10.1182/blood-2015-03-635169 This study from the Stanford group is a large study that evaluted the role of MRD in surveillance of patients with DLBCL. They detected molecular disease in peripheral blood via immunoglobulin high-throughouput sequencing and showed MRD peformed better than traditional PET/CT to detect relapse.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    •• Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541–9.  https://doi.org/10.1016/S1470-2045(15)70106-3 Investigators at the National Cancer Institute published a large study evaluating the role of MRD testing in peripheral blood via IgNGS in patients with DLBCL. They collected samples from 126 patients for a median of 11 years and showed MRD was a useful marker for surveillance.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–65.  https://doi.org/10.1056/NEJMra1706174.CrossRefPubMedGoogle Scholar
  16. 16.
    Herrera AF, Armand P. Minimal residual disease assessment in lymphoma: methods and applications. J Clin Oncol. 2017;35(34):3877–87.  https://doi.org/10.1200/JCO.2017.74.5281.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Bottcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica. 2008;93(4):551–9.  https://doi.org/10.3324/haematol.11267.CrossRefPubMedGoogle Scholar
  18. 18.
    Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood. 2017;130(4):440–52.  https://doi.org/10.1182/blood-2017-03-735639.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101(3):336–45.  https://doi.org/10.3324/haematol.2015.134957.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018;8(8):74.  https://doi.org/10.1038/s41408-018-0111-6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Darrah JM, Herrera AF. Updates on circulating tumor DNA assessment in lymphoma. Curr Hematol Malig Rep. 2018;13(5):348–55.  https://doi.org/10.1007/s11899-018-0468-4.CrossRefPubMedGoogle Scholar
  22. 22.
    •• Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harslof LB, Pedersen OB, et al. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics. 2016;8(1):95.  https://doi.org/10.1186/s13148-016-0261-y This study examined aberrant methylation levels in plasma via pyrosequencing at diagnosis and throughout treatment in 74 patients with DLBCL. They found that aberrant DAPK1 methylation was an independent progonostic factor for overall survival. Additionally, patients who were long term survivers lost their methylation after treatment.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    • Wedge E, Hansen JW, Garde C, Asmar F, Tholstrup D, Kristensen SS, et al. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma. Am J Hematol. 2017;92(7):689–94.  https://doi.org/10.1002/ajh.24751 This study assessed global hypomethylation in plasma samples via pyrosequencing in 74 patient with DLBCL. Global hypomethylation was associated with poor surivival.CrossRefPubMedGoogle Scholar
  24. 24.
    Delaney C, Garg SK, Yung R. Analysis of DNA methylation by pyrosequencing. Methods Mol Biol. 2015;1343:249–64.  https://doi.org/10.1007/978-1-4939-2963-4_19.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wu FT, Lu L, Xu W, Li JY. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Ann Hematol. 2018;98:255–69.  https://doi.org/10.1007/s00277-018-3529-9.CrossRefPubMedGoogle Scholar
  26. 26.
    • Klein EA, Hubbell E, Maddala T, Aravanis A, Beausang JF, Filippova D, et al. Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: the Circulating Cell-free Genome Atlas (CCGA) study. J Clin Oncol. 2018;36(15_suppl):12021.  https://doi.org/10.1200/JCO.2018.36.15_suppl.12021 This abstract discusses prelimary results from an ongoing, prospective, multi-center, observational study evaluating the used of cell free DNA as a screening tool. Cell free DNA is analyzed via multiple techniques in patients with newly diagnosed malignancies and in normal patients. Preliminary results show whole genome bisulfite sequencing for methylation is the most sensitive for detecting several tumor types including lymphoma.CrossRefGoogle Scholar
  27. 27.
    Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–12.  https://doi.org/10.1073/pnas.1508736112.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 2015;1(6):814–9.  https://doi.org/10.1001/jamaoncol.2015.1883.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947–57.  https://doi.org/10.1182/blood-2016-05-719641 This study collected utilized CAPP-seq to correctly identify DLBCL-associated mutations and identified more mutations than tissue biopsies. MRD was monitored throughout treatment and responding patients had rapid clearance of mutations.CrossRefPubMedGoogle Scholar
  30. 30.
    •• Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.  https://doi.org/10.1126/scitranslmed.aai8545 Utilizing CAPP-Seq the Stanford group evaluated ctDNA in 92 lymphoma patients and 24 healthy patients. ctDNA levels in plasma at diangosis were predictive of outcomes, could idenify cell of origin, and could be used to track clonal evolution.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90.  https://doi.org/10.1038/s41591-018-0016-8.CrossRefPubMedGoogle Scholar
  32. 32.
    Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407.  https://doi.org/10.1056/NEJMoa1801445.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–7.  https://doi.org/10.1182/blood-2013-11-536433.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079–87.  https://doi.org/10.1200/JCO.2011.35.4423.CrossRefPubMedGoogle Scholar
  35. 35.
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Cancer Netw. 2016;14(2):196–231.CrossRefGoogle Scholar
  36. 36.
    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.  https://doi.org/10.1182/blood-2003-05-1545.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845–53.  https://doi.org/10.1200/JCO.2018.78.5246 The Stanford group utilized CAPP-Seq to detect MRD in 217 patients with DLBCL. They found that pretreatment ctDNA levels were predictive of response to therapy. Additionally, after front-line therapy depth of MRD was predictive of outcomes.CrossRefPubMedGoogle Scholar
  38. 38.
    •• Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–94.  https://doi.org/10.1182/blood-2016-02-699520 This was a phase 2 study that incorporated MRD into the study design. They evaluated panobinostat with or without rituximab in 40 patients with relapsed DLBCL and found that MRD levels at day 15 were strongly associated with lack of response.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Camus V, Miloudi H, Taly A, Sola B, Jardin F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10(1):47.  https://doi.org/10.1186/s13045-017-0412-4.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Dubois S, Mareschal S, Picquenot JM, Viailly PJ, Bohers E, Cornic M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015;6(18):16712–24.  https://doi.org/10.18632/oncotarget.3154.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6.  https://doi.org/10.1038/nm.3884.CrossRefPubMedGoogle Scholar
  42. 42.
    Camus V, Sarafan-Vasseur N, Bohers E, Dubois S, Mareschal S, Bertrand P, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(9):2171–9.  https://doi.org/10.3109/10428194.2016.1139703.CrossRefPubMedGoogle Scholar
  43. 43.
    • Hossain NM, Dahiya S, Le R, Abramian AM, Kong KA, Muffly LS, et al. Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. Leuk Lymphoma. 2018:1–4.  https://doi.org/10.1080/10428194.2018.1474463 This is a small observational report of 6 patients with DLBCL who underwent CAR-T therapy targeting CD19. MRD was assessed using IgNGS from plasma and correlated with both clinical and radiographic outcomes. Based on these results a larger, multi-insitutional study is underway.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Taussig Cancer InstituteCleveland ClinicClevelandUSA

Personalised recommendations